
|Videos|December 5, 2022
Latest research supporting stereotactic radiotherapy for oligometastatic renal cell carcinoma
Author(s)Urology Times staff
Advertisement
At the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Individualizing androgen pathway therapy in mCSPC
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












